Metsera, Inc. (NASDAQ:MTSR) is one of the 11 Hot New Stocks to Invest in Now. On June 22, Metsera, Inc. (NASDAQ:MTSR) ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

Methode Electronics posted adjusted loss of 77 cents per share, missing market estimates of earnings of 4 cents per share, ...

Metsera is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could ...

About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases.

Wells Fargo emphasized that Metsera’s long half-life drugs may provide improved tolerability by enabling gradual buildup of drug exposure and avoiding fluctuations that increase adverse events. The ...

Wells Fargo emphasized that Metsera’s long half-life drugs may provide improved tolerability by enabling gradual buildup of drug exposure and avoiding fluctuations that increase adverse events.

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera” or the "Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for ...

Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.

Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and ...